FSUE Moscow Endocrine Plant (hereinafter as the Enterprise) as part of a collective exhibit under the guidance of the Ministry of Industry and Trade of Russia took part in “Pharmmedprom-2019” forum (hereinafter as the forum), which was held as part of the International academic and research forum “Russian Health Care Week - 2019”.
Along with the traditionally manufactured products of social importance, the latest technologies of the Enterprise were presented. In the current year, the Enterprise’s nomenclature was replenished by such medicinal products as:
• “Morphine long” (International Non-proprietary Name (hereinafter as INPN) - Morphine). Film-coated extended release tablets, 10 mg, 30 mg, 60 mg, and 100 mg. The drug product is used for long-lasting relief of explicit and chronic pain syndrome.
• “Lorazepam” (INPN - Lorazepam). Film-coated tablets, 1.0 mg and 2.5 mg. The drug is used in neuroticism, sleep disorders, in skeletal muscles hypertension, for pre-medication in diagnostic procedures and surgical interventions.
• “Immunotim” (INPN - Thymus extract). Lyophilizate for preparation of solution for intramuscular injection, 10 mg. Belongs to “immunostimulative drug” pharmacotherapeutic group and is used in immunodeficiency in adults and in children over the age of 6 months.
• “Nefopamum” (INPN - Nefopamum). Solution for infusions and intramuscular administration 10 mg/mL. The product is non-narcotic analgetic of central action and is used for symptomatic treatment of the acute pain syndrome, including post-surgery pain in adults and children over the age of 15 months.
The participants and hosts of the forum were especially interested in the Enterprise’s project on organization in Russia of domestic competitive production of active pharmaceutical ingridients of animal and vegetable origin and produced by chemical synthesis at “Pochep” Enterprise facility in Bryansk oblast.
Also the important achievements in 2019 were Enterprise’s receiving the European Union GMP compliance certificate on the line for production of injectable sterile medicinal products No. ZVA/LV/2019/002H dd. 04.02.2019 and confirmation of the competence of the quality control laboratory department in RusAccreditation as per the standard GOST ISO/МEК 17025 (accreditation certificate No. RU.RA.21Н019 dd. 22.01.2019), which increases Enterprise’s export potential and its attractiveness for potential partners in the sphere of contract manufacturing, development and quality control of the pharmaceutical products.
Comment type is not specified in the component properties.